References
- Furlanut, M, Brollo, L, Lugatti, E, Di Qual, E, Dolcet, F, Talmassons, G, et al . Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother. 2003;51:101–6.
- Langtry HD , Lamb HM , Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs. 1998;56:487–515.
- Preston SL , Drusano GL , Berman AL , Fowler CL , Chow AT , Dornseif B , et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother. 1998;42(5):1098–104.
- Preston SL , Drusano GL , Berman AL , Fowler CL , Chow AT , Dornseif B , et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998;279:125–9.
- Scaglione F , Paraboni L . Pharmacokinetics/pharmacodynamics of antibacterial in the intensive care unit: setting appropriate dosing regimens. Int J Antimicrob Agents. 2008;32(4):294–301.
- Schentag JJ , Meagher AK , Forrest A , Fluoroquinolone AUIC . break points and the link to bacterial killing rates. Part1: in vitro and animal models. Ann Pharmacother. 2003;37(9):1287–98.
- Schentag JJ , Meagher AK , Forrest A . Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part2: human trials. Ann Pharmacother. 2003;37(10):1478–88.
- Forrest A , Ballow CH , Nix DE , Birmingham MC , Schentag JJ . Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother. 1993;37(5):1065–72.
- Tam VH , McKinnon PS , Akins RL , Drusano GL , Rybak MJ . Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother. 2003;47(6):1853–61.
- Murphy JE , Gillespie DE , Bateman CV . Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am J Health Syst Pharm. 2006;63(23):2365–70.
- Sánchez JL , Dominguez AR , Lane JR , Anderson PO , Capparelli EV , Cornejo-Bravo JM . Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010;48(8):525–33.
- Crandon JL , Ariano RE , Zelenitsky SA , Nicasio AM , Kuti JL , Nicolau DP . Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med. 2011;37(4):632–8.
- Karlsson MO , Savic RM . Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82:17–20.
- Simpson JA , Jamsen KM , Price RN , White NJ , Lindegardh N , Tarning J , et al. Towards optimal design of anti-malarial pharmacokinetic studies. Malar J. 2009;8:189.
- Green B , Duffull SB . Prospective evaluation of a D-optimal designed population pharmacokinetic study. J Pharmacokinet Pharmacodyn. 2003;30:145–61.